

Global Anti-ANGPTL3 Antibody Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/G8A4F73F0D7BEN.html>

Date: January 2026

Pages: 70

Price: US\$ 3,480.00 (Single User License)

ID: G8A4F73F0D7BEN

Abstracts

According to our (Global Info Research) latest study, the global Anti-ANGPTL3 Antibody market size was valued at US\$ 158 million in 2025 and is forecast to a readjusted size of US\$ 313 million by 2032 with a CAGR of 9.5% during review period.

In 2025, global Anti-ANGPTL3 Antibody production reached approximately 18.88 K Boxes, with an average global market price of around 8121 USD per Box.

An anti-ANGPTL3 antibody is a monoclonal antibody designed to bind and inhibit angiopoietin-like protein 3 (ANGPTL3), a circulating liver-derived protein that regulates lipid metabolism by suppressing lipoprotein lipase (and related pathways). By neutralizing ANGPTL3's activity, these antibodies aim to increase triglyceride-rich lipoprotein clearance and reduce atherogenic lipids (such as LDL cholesterol and triglycerides), and are used or developed for treating severe dyslipidemias and reducing cardiovascular risk. Evolocumab is the only marketed anti-ANGPTL3 antibody globally. It has been approved by the US FDA for the treatment of homozygous familial hypercholesterolemia (HoFH).

Anti-ANGPTL3 antibodies are compelling because they target a well-defined, liver-driven control point in lipid metabolism that can address a persistent industry pain point: a subset of patients remain at high cardiovascular risk despite today's standard lipid-lowering options, either because of severe inherited dyslipidemias, mixed lipid abnormalities, intolerance, or residual risk that is not fully captured by LDL-centric approaches. By neutralizing ANGPTL3, these antibodies can reduce atherogenic lipoprotein burden through mechanisms that are complementary to statins and PCSK9 inhibitors, offering clinicians a differentiated tool when conventional pathways plateau

and enabling a precision-medicine narrative for complex lipid phenotypes where triglycerides, remnants, and broader dyslipidemia matter. The category is being propelled by structural drivers that have reshaped cardiometabolic drug development: rising global prevalence of obesity and diabetes, stronger emphasis on preventing costly downstream events, increasing sophistication in genetic and biomarker-enabled patient identification, and growing confidence among payers and health systems in high-value biologics that demonstrate meaningful risk reduction in well-defined populations. Anti-ANGPTL3 antibodies have credible market runway as evidence and clinical experience mature, positioning expands from rare and refractory patients toward broader high-risk segments where unmet need remains, and combination strategies with established lipid therapies become more clearly standardized, making the class an attractive long-term opportunity within the evolving cardiometabolic landscape without relying on exaggerated claims.

The upstream raw materials for anti-ANGPTL3 antibody mainly include ANGPTL3 recombinant protein, CHO cells, etc. Typical raw material suppliers include Thermo Fisher, Merck, Pall, etc. The downstream application is mainly for people with high blood lipids.

The production capacity of anti-ANGPTL3 antibody production lines varies greatly depending on the type of drug molecule, process complexity, equipment scale, and production mode. The industry gross profit margin is usually in the range of 60%-80%.

This report is a detailed and comprehensive analysis for global Anti-ANGPTL3 Antibody market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Anti-ANGPTL3 Antibody market size and forecasts, in consumption value (\$ Million), sales quantity (K Boxes), and average selling prices (USD/Box), 2021-2032

Global Anti-ANGPTL3 Antibody market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Boxes), and average selling prices (USD/Box), 2021-2032

Global Anti-ANGPTL3 Antibody market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Boxes), and average selling prices (USD/Box), 2021-2032

Global Anti-ANGPTL3 Antibody market shares of main players, shipments in revenue (\$ Million), sales quantity (K Boxes), and ASP (USD/Box), 2021-2026

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Anti-ANGPTL3 Antibody

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Anti-ANGPTL3 Antibody market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Regeneron, Eli Lilly, Jiangsu Hengrui Medicine, Cspc Holdings, Suzhou Ribo Life Science, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Anti-ANGPTL3 Antibody market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Direct Neutralization

Indirect Inhibition

Others

Market segment by Action Mechanism

Direct Neutralization

Indirect Inhibition

Others

Market segment by Route of Administration

Intravenous Injection

Subcutaneous Injection

Market segment by Application

Homozygous Familial Hypercholesterolaemia (HoFH)

Others

Major players covered

Regeneron

Eli Lilly

Jiangsu Hengrui Medicine

Cspc Holdings

Suzhou Ribo Life Science

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Anti-ANGPTL3 Antibody product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Anti-ANGPTL3 Antibody, with price, sales quantity, revenue, and global market share of Anti-ANGPTL3 Antibody from 2021 to 2026.

Chapter 3, the Anti-ANGPTL3 Antibody competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Anti-ANGPTL3 Antibody breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026. and Anti-ANGPTL3 Antibody market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Anti-ANGPTL3 Antibody.

Chapter 14 and 15, to describe Anti-ANGPTL3 Antibody sales channel, distributors, customers, research findings and conclusion.

I would like to order

Product name: Global Anti-ANGPTL3 Antibody Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/G8A4F73F0D7BEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8A4F73F0D7BEN.html>